Lisani M 5mg/10mg Tablet is a combination medication containing Levocetirizine 5mg and Montelukast 10mg, indicated for the management of allergic rhinitis and chronic asthma. Levocetirizine, a third-generation non-sedating antihistamine, selectively inhibits peripheral H1 receptors, thereby reducing symptoms such as sneezing, nasal congestion, rhinorrhea, and itching associated with allergic conditions. Montelukast, a leukotriene receptor antagonist, blocks leukotriene D4 at the cysteinyl leukotriene receptor, contributing to decreased bronchoconstriction, inflammation, and mucus production in the airways. The synergistic action of these agents provides comprehensive relief from allergic symptoms and improves pulmonary function in patients with asthma. Lisani M is typically prescribed for adults and adolescents aged 15 years and above, with dosing tailored according to clinical response. It is well-tolerated, with a low incidence of adverse effects; common side effects may include headache, fatigue, and gastrointestinal discomfort. Caution is advised in patients with hepatic impairment or a history of neuropsychiatric events. This combination therapy offers an effective approach for patients requiring concurrent management of allergic rhinitis and asthma, enhancing quality of life through improved symptom control. Use under medical supervision is recommended to ensure optimal therapeutic outcomes.